Cyclocreatine-13C3

Cyclocreatine-13C3 is the 13C-labeled Cyclocreatine. Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer[1][2][3][4][5].

12352005

ATP Synthase; Isotope-Labeled Compounds

Membrane Transporter/Ion Channel; Others

Cancer; Metabolic Disease; Neurological Disease; Cardiovascular Disease

N[13C]1=NCCN1[13CH2][13C](O)=O

C2 13C3H9N3O2

146.12

[1]Salwa A Elgebaly, et al. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion. Expert Rev Cardiovasc Ther. 2019 Sep;17 (9) :683-697.|[2]Tyler K Ulland, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 2017 Aug 10;170 (4) :649-663.e13.|[3]Patel R, et al. Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression[J]. Cancer Res. 2022 Jul 18;82 (14) :2565-2575.|[4]Patel R, et al. Cyclocreatine suppresses prostate tumorigenesis through dual effects on SAM and creatine metabolism[J]. bioRxiv, 2021: 2021.02. 26.432994.|[5]Cacciante F, et al. Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency[J]. Sci Rep. 2020 Oct 27;10 (1) :18361.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W017540S/

Isotope-Labeled Compounds

No Development Reported